SimianX AI LogoSimianX AI

Record mula sa primary source

Decision-gradePagbabago sa trial registry

Unang pasyente ang binigyan ng dosis ng Beam Therapeutics sa pivotal AATD cohort ng BEAM-302

Unang pasyente ang binigyan ng dosis ng Beam sa global pivotal cohort ng patuloy na Phase 1/2 trial ng BEAM-302 para sa AATD-associated lung disease, mayroon o walang liver disease. Ang cohort ay dinisenyo upang suportahan ang potensyal na accelerated approval path sa Estados Unidos. Na-update rin ang clinical data para sa BEAM-302 at napili para sa late-breaking oral presentation sa ERS Congress 2026 (Setyembre 5-9, 2026).

Mahahalagang fact

Na-file
Ago 4, 2026, 11:09 AM
Kaganapan
Pagbabago sa trial registry
Direksyon
Positibo
Kumpanya
BEAMBeam Therapeutics
Asset
BEAM-302
Pinagmulan
SEC 8-K
Kumpiyansa
May source

Sipi mula sa source

EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Clinical Trial Start-up Activities Underway Following U.S. FDA Clearance of Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU) Ended Second Quarter 2026 with $1.2 Billion in Cash,

SEC 8-K

Higit pa tungkol sa asset na ito